Lutz Frankenstein

Lutz Frankenstein

Auto-generated profile, based on publicly available information

Lutz Frankenstein

Department of Cardiology, Angiology and Pulmology, University Hospital Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
LFLutz Frankenstein
Lutz Frankenstein
AWAlan H.B. Wu
Alan H.B. Wu
KHKlaus Hallermayer
Klaus Hallermayer
FWFrank H Wians
Frank H Wians
EGEvangelos Giannitsis
Evangelos Giannitsis
HKHugo A Katus
Hugo A Katus
BACKGROUND: Acute myocardial infarction is defined by a troponin concentration >99th percentile with an acute increase and/or decrease, the magnitude of which has not yet been well defined. To aid the interpretation of changes in cardiac troponin concentration, we sought to establish biological variation and reference change values (RCVs) by applying both the normal and lognormal approaches for cardiac troponin T (cTnT) sampled at hourly and weekly intervals in healthy individuals and measured on the Roche E 170 and Elecsys® 2010 automated platforms. METHODS: High-sensitivity cTnT (hsTnT) was measured at baseline, and after 1, 2, 3, and 4 h and after 1, 2, 3, and 4 weeks in 20 and 17 healthy individuals, respectively. A healthy status was established by physical examination, MRI analysis at rest and during dobutamine stress, lung function testing, and blood sample testing. RESULTS: Hourly total and within-individual CVs were 18% and 15%, respectively, for the E 170 assay, and 24% and 21%, respectively, for the Elecsys 2010 assay. Weekly total and within-individual CVs for these assays were 32% and 31%, respectively, for the E 170 assay, and 32% and 30%, respectively, for the Elecsys 2010 assay. The RCVs for the E 170 and Elecsys 2010 assays were ±46% and ±62% (hourly), respectively, and ±87% and ±86% (weekly), respectively. The corresponding lognormal values were +64%/−39% and +90%/−47% (hourly), and +138%/−58% and +135%/−58% (weekly). CONCLUSIONS: RCVs appear attractive for interpreting hsTnT results. The short-term biological variation of hsTnT is low but becomes somewhat more important at intermediate sampling intervals. Knowledge of this variation is important for interpreting results from patients in whom cTnT values increase from low concentrations.

1 September 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
TTTobias Täger
Tobias Täger
WHWiebke Hanholz
Wiebke Hanholz
RCRita Cebola
Rita Cebola
HFHanna Fröhlich
Hanna Fröhlich
JFJennifer Franke
Jennifer Franke
LFLutz Frankenstein
Lutz Frankenstein

20 April 2020 in Heart Failure Reviews
Verified
Journal Article
Open access
PDF file
TTTobias Täger
Tobias Täger
DADan Atar
Dan Atar
SAStefan Agewall
Stefan Agewall
HKHugo A. Katus
Hugo A. Katus
MGMorten Grundtvig
Morten Grundtvig
LFLutz Frankenstein
Lutz Frankenstein
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2D). The comparative efficacy of individual SGLT2i remains unclear. We searched PubMed, www.clinicaltrials.gov and the Cochrane Central Register of Controlled Trials for randomised controlled trials exploring the use of canagliflozin, dapagliflozin, empagliflozin or ertugliflozin in patients with T2D. Comparators included placebo or any other active treatment. The primary endpoint was all-cause mortality. Secondary endpoints were cardiovascular mortality and worsening heart failure (HF). Evidence was synthesised using network meta-analysis (NMA). Sixty-four trials reporting on 74,874 patients were included. The overall quality of evidence was high. When compared with placebo, empagliflozin and canagliflozin improved all three endpoints, whereas dapagliflozin improved worsening HF. When compared with other SGLT2i, empagliflozin was superior for all-cause and cardiovascular mortality reduction. Empagliflozin, canagliflozin and dapagliflozin had similar effects on improving worsening HF. Ertugliflozin had no effect on any of the three endpoints investigated. Sensitivity analyses including extension periods of trials or excluding studies with a treatment duration of < 52 weeks confirmed the main results. Similar results were obtained when restricting mortality analyses to patients included in cardiovascular outcome trials (n = 38,719). Empagliflozin and canagliflozin improved survival with empagliflozin being superior to the other SGLT2i. Empagliflozin, canagliflozin and dapagliflozin had similar effects on improving worsening HF. Prospective head-to-head comparisons would be needed to confirm these results.

22 April 2017 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
HFHanna Fröhlich
Hanna Fröhlich
LTLorella Torres
Lorella Torres
TTTobias Täger
Tobias Täger
DSDieter Schellberg
Dieter Schellberg
ACAnna Corletto
Anna Corletto
LFLutz Frankenstein
Lutz Frankenstein

20 May 2008 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LFLutz Frankenstein
Lutz Frankenstein
ARAndrew Remppis
Andrew Remppis
MNManfred Nelles
Manfred Nelles
BSBernd Schaelling
Bernd Schaelling
DSDieter Schellberg
Dieter Schellberg
CZChristian Zugck
Christian Zugck
To investigate the relationship between body mass index (BMI) and N-terminal pro-brain natriuretic peptide (NTproBNP) level and resultant prognostic capacity in chronic heart failure (CHF) controlled for known confounders. We formed 206 triplets of patients (n = 618) with stable systolic CHF matched with respect to age, sex, renal function (MDRD, modification of diet in renal disease formula), and NYHA class, each with a BMI >30 kg/m2 (group 3), 20–24.9 kg/m2 (group 1), and 25–29.9 kg/m2 (group 2). BMI conveys a 4% drop in NTproBNP per unit increase. This influence remained significant after correction for age, sex, MDRD, NYHA, heart rate, rhythm, and ejection fraction. NTproBNP remained an independent predictor of adverse outcome after correction for age, sex, BMI, NYHA, MDRD, and ejection fraction. Despite numerical differences, prognostic power was comparable between BMI groups (log-transformed NTproBNP; group 1: hazard ratio (HR) 1.435, 95% CI 1.046–1.967, χ2 5.02, P = 0.03; group 2: HR 1.604, 95% CI 1.203–2.138, χ2 10.36, P = 0.001; group 3: HR 1.735, 95% CI 1.302–2.313, χ2 14.12, P = 0.0002) (P = NS, all). An NTproBNP correction factor was calculated. Even matched for NYHA, age, sex, and renal function, BMI exerts a significant and independent inverse influence on NTproBNP in patients with stable CHF. NTproBNP retained equal statistical power in all three BMI groups.

8 September 2021 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
TTTobias Täger
Tobias Täger
LFLutz Frankenstein
Lutz Frankenstein
DADan Atar
Dan Atar
SAStefan Agewall
Stefan Agewall
NFNorbert Frey
Norbert Frey
HFHanna Fröhlich
Hanna Fröhlich
Background: Receptor selectivity of sodium-glucose cotransporter-2 inhibitors (SGLT2i) varies greatly between agents. The overall improvement of cardiovascular (CV) outcomes in heart failure (HF) patients varies between trials. We, therefore, evaluated the comparative efficacy of individual SGLT2i and the influence of their respective receptor selectivity thereon. Methods: We identified randomized controlled trials investigating the use of SGLT2i in patients with HF—either as the target cohort or as a subgroup of it. Comparators included placebo or any other active treatment. The primary endpoint was the composite of hospitalization for HF or CV death. Secondary outcomes included all-cause mortality, CV mortality, hospitalization for HF, worsening renal function (RF), and the composite of worsening RF or CV death. Evidence was synthesized using network meta-analysis. In addition, the impact of receptor selectivity on outcomes was analysed using meta-regression. Results: We identified 18,265 patients included in 22 trials. Compared to placebo, selective and non-selective SGLT2i improved fatal and non-fatal HF events. Head-to-head comparisons suggest superior efficacy with sotagliflozin as compared to dapagliflozin, empagliflozin or ertugliflozin. No significant difference was found between canagliflozin and sotagliflozin. Meta-regression analyses show a decreasing benefit on HF events with increasing receptor selectivity of SGLT2i. In contrast, receptor selectivity did not affect mortality and renal endpoints and no significant difference between individual SGLT2i was noted. Conclusion: Our data point towards a class-effect of SGLT2i on mortality and renal outcomes. However, non-selective SGLT2i such as sotagliflozin may be superior to highly selective SGLT2i in terms of HF outcomes.